138 related articles for article (PubMed ID: 18467311)
1. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy.
Heron DE; Brufsky A; Beriwal S; Kurman M
Ann Oncol; 2008 Sep; 19(9):1639-43. PubMed ID: 18467311
[TBL] [Abstract][Full Text] [Related]
2. Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases.
Paravati AJ; Russo AL; Aitken C
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):506-10. PubMed ID: 20888141
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow recovery following use of systemic (153)Sm-lexidronam and (89)Sr-chloride for bone pain palliation after myelosuppressive therapy.
Papatheofanis FJ; Najib MM
Int J Radiat Biol; 2009 May; 85(5):448-53. PubMed ID: 19437245
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
Sartor O; Reid RH; Bushnell DL; Quick DP; Ell PJ
Cancer; 2007 Feb; 109(3):637-43. PubMed ID: 17167764
[TBL] [Abstract][Full Text] [Related]
5. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
Ripamonti C; Fagnoni E; Campa T; Seregni E; Maccauro M; Bombardieri E
Support Care Cancer; 2007 Mar; 15(3):339-42. PubMed ID: 16967302
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
Tu SM; Mathew P; Wong FC; Jones D; Johnson MM; Logothetis CJ
J Clin Oncol; 2009 Jul; 27(20):3319-24. PubMed ID: 19414670
[TBL] [Abstract][Full Text] [Related]
7. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
Dolezal J; Vizd'a J; Cermáková E
Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
[TBL] [Abstract][Full Text] [Related]
8. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
9. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP.
Pacilio M; Ventroni G; Basile C; Ialongo P; Becci D; Mango L
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):238-52. PubMed ID: 24077786
[TBL] [Abstract][Full Text] [Related]
10. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.
Sartor O; Reid RH; Hoskin PJ; Quick DP; Ell PJ; Coleman RE; Kotler JA; Freeman LM; Olivier P;
Urology; 2004 May; 63(5):940-5. PubMed ID: 15134985
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain.
Menda Y; Bushnell DL; Williams RD; Miller S; Thomas MO
Clin Nucl Med; 2000 Sep; 25(9):698-700. PubMed ID: 10983757
[TBL] [Abstract][Full Text] [Related]
12. Samarium-153 lexidronam for painful bone metastases.
Med Lett Drugs Ther; 1997 Aug; 39(1008):83-4. PubMed ID: 9286284
[No Abstract] [Full Text] [Related]
13. Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005).
Barnard SM; Zuber RM; Moore AS
J Am Vet Med Assoc; 2007 Jun; 230(12):1877-81. PubMed ID: 17571994
[TBL] [Abstract][Full Text] [Related]
14. 153Sm-EDTMP for bone pain palliation in skeletal metastases.
Maini CL; Bergomi S; Romano L; Sciuto R
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S171-8. PubMed ID: 15127241
[TBL] [Abstract][Full Text] [Related]
15. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.
Sapienza MT; Ono CR; Guimarães MI; Watanabe T; Costa PA; Buchpiguel CA
Rev Hosp Clin Fac Med Sao Paulo; 2004 Dec; 59(6):321-8. PubMed ID: 15654484
[TBL] [Abstract][Full Text] [Related]
16. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
17. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases.
Tripathi M; Singhal T; Chandrasekhar N; Kumar P; Bal C; Jhulka PK; Bandopadhyaya G; Malhotra A
Indian J Cancer; 2006; 43(2):86-92. PubMed ID: 16790946
[TBL] [Abstract][Full Text] [Related]
18. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
Resche I; Chatal JF; Pecking A; Ell P; Duchesne G; Rubens R; Fogelman I; Houston S; Fauser A; Fischer M; Wilkins D
Eur J Cancer; 1997 Sep; 33(10):1583-91. PubMed ID: 9389919
[TBL] [Abstract][Full Text] [Related]
19. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA
J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068
[TBL] [Abstract][Full Text] [Related]
20. The Vienna protocol and perspectives in radionuclide therapy.
Sinzinger H; Palumbo B; Ozker K
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):420-30. PubMed ID: 21738115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
